Peptides · Peptide comparison
Lixisenatide vs Retatrutide
Short-acting prandial GLP-1 receptor agonist for postprandial glucose control
The world's first triple-action weight loss peptide that simultaneously activates three hormone receptors—GIP, GLP-1, and glucagon—delivering unprecedented weight loss results of up to 24% body weight in clinical trials [1][2].
- Weight Management
- Weight Management
At a glance
Quick comparison
Efficacy
Benefit ratings
Blood Sugar Control
Cardiovascular Safety
Weight Management
Weight Loss Power
Metabolic Health
Appetite Control
Technical data
Compound specifications
Lixisenatide
- Molecular formula
- C215H347N61O65S
- Molecular weight
- 4,858 Da
- Half-life
- 2.8-3 hours
- Bioavailability
- 55% subcutaneous bioavailability
- CAS number
- 320367-13-3
Retatrutide
- Molecular formula
- C221H342N46O68
- Molecular weight
- 4731 g/mol
- Half-life
- ~6 days (allows once-weekly dosing)
- Bioavailability
- High via subcutaneous injection
- CAS number
- 2381089-83-2
Protocols
Dosing compared
Lixisenatide
Subcutaneous
- Weeks 1-210 mcgOnce daily · Days 1-14FDA-label (Adlyxin) starting dose given once daily for 14 days using the green starter pen; injected in abdomen, thigh, or upper arm within one hour before the first meal of the day [6].
- Day 1520 mcgOnce daily · From day 15 onwardFDA-label maintenance dose, started on day 15 using the burgundy pen for ongoing type 2 diabetes glycemic control [6].
Retatrutide
Subcutaneous
- Weeks 1-42 mgOnce weekly · Weeks 1-4 (then escalate 2 mg every 4 weeks)Phase 2 obesity trial initiated higher-dose arms at 2 mg weekly with stepwise 2 mg increases every 4 weeks to limit GI effects [1].
- Maintenance after titration4-8 mgOnce weekly · Maintenance after titrationMid-range maintenance doses; 8 mg produced ~22% mean weight loss at 48 weeks in the phase 2 trial [1][3].
- Maintenance (highest studied)12 mgOnce weekly · Maintenance (highest studied)Highest studied dose; produced ~24% mean weight reduction at 48 weeks [1]. Still investigational (not FDA-approved).
Applications
Best suited for
Lixisenatide
- Managing postprandial hyperglycemia in type 2 diabetes
- Lixisenatide is particularly well-suited for individuals focused on managing postprandial hyperglycemia in type 2 diabetes. Research and clinical experience suggest meaningful benefits in this area when used as part of a comprehensive treatment approach.
- Improving glycemic control as add-on to oral antidiabetics
- Lixisenatide is particularly well-suited for individuals focused on improving glycemic control as add-on to oral antidiabetics. Research and clinical experience suggest meaningful benefits in this area when used as part of a comprehensive treatment approach.
- Supporting weight management in T2DM patients
- Lixisenatide is particularly well-suited for individuals focused on supporting weight management in t2dm patients. Research and clinical experience suggest meaningful benefits in this area when used as part of a comprehensive treatment approach.
- Combination therapy with basal insulin glargine
- Lixisenatide is particularly well-suited for individuals focused on combination therapy with basal insulin glargine. Research and clinical experience suggest meaningful benefits in this area when used as part of a comprehensive treatment approach.
Retatrutide
- Significant Obesity Management
- If you need to lose a substantial amount of weight, retatrutide is showing unprecedented results. Phase 2 trials demonstrated average weight loss of 24% at the highest dose—that's nearly 60 pounds for someone weighing 250 lbs [1]. No other medication has matched this [1].
- Type 2 Diabetes with Obesity
- Retatrutide tackles both problems at once. It dramatically improves blood sugar control (HbA1c reductions of up to 2%) while delivering major weight loss [6]. The dual benefit makes it especially valuable for diabetics struggling with weight.
- Metabolic Syndrome Warriors
- If you're dealing with the cluster of issues that includes high blood sugar, excess belly fat, abnormal cholesterol, and high blood pressure, retatrutide's triple mechanism attacks multiple aspects of metabolic dysfunction simultaneously [5].
- Fatty Liver Disease (MASLD)
- Early research shows retatrutide may significantly reduce liver fat [7]. For people with non-alcoholic fatty liver disease, this peptide offers hope through weight loss plus direct metabolic improvements that benefit liver health.
Safety profile
Side effects
Lixisenatide
Common
- Nausea
- Vomiting
- Diarrhea
- Headache
Uncommon
- Injection Site Reactions
Serious
- Acute Pancreatitis
Retatrutide
Common
- Nausea
- Diarrhea
- Constipation
- Decreased appetite
Uncommon
- Increased heart rate
- Injection site reactions
Serious
- Pancreatitis
- Gallbladder problems
Research status
Safety & evidence
Lixisenatide
- Evidence level
- Strong human trials (Phase 3 or FDA approved)
- FDA status
- FDA approved for this use
- Safety overview
- Lixisenatide (ADLYXIN in the US, Lyxumia in the EU) is an FDA-approved GLP-1 receptor agonist for type 2 diabetes; its safety record comes from the GetGoal phase 3 trials and the ELIXA cardiovascular outcomes trial. [1][6] In the pooled placebo-controlled trials, gastrointestinal reactions affected 39.7% of patients against 18.4% on placebo, mostly in the first 3 weeks; nausea affected 25% and vomiting 10%. [6] Labelled warnings cover anaphylaxis and serious hypersensitivity, pancreatitis (21 cases on lixisenatide against 14 on comparators), hypoglycemia when combined with a sulfonylurea or basal insulin, acute kidney injury after severe GI fluid loss, antibody formation and gallbladder disease. [6] Unlike the long-acting GLP-1 agonists, its label carries no boxed thyroid C-cell tumor warning. [6]
Contraindications
- Known hypersensitivity to lixisenatide or excipients [6]
Retatrutide
- Evidence level
- Moderate human trials (Phase 1-2)
- FDA status
- Research compound
- Safety overview
- Retatrutide has shown a generally favorable safety profile in Phase 1 and Phase 2 clinical trials involving over 600 participants [1][6]. Most side effects are gastrointestinal and tend to improve over time [3]. The medication appears well-tolerated when doses are increased gradually. No major safety signals have emerged, but larger Phase 3 trials are still ongoing [3].
Contraindications
- Personal or family history of medullary thyroid carcinoma (MTC)
- Multiple Endocrine Neoplasia syndrome type 2 (MEN 2)
- Pregnancy or planning to become pregnant
- History of severe pancreatitis
- Known allergy to GLP-1 receptor agonists
Decision guide
Which is right for you?
Lixisenatide
Choose Lixisenatide if…
- Managing postprandial hyperglycemia in type 2 diabetes
- Improving glycemic control as add-on to oral antidiabetics
- Supporting weight management in T2DM patients
- Combination therapy with basal insulin glargine
Retatrutide
Choose Retatrutide if…
- Significant weight loss
- Type 2 diabetes management
- Metabolic health improvement
- Body composition optimization